In a landmark decision for British healthcare and scientific innovation, the UK's Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval for the first mRNA vaccine to be manufactured domestically within the country. This historic move involves Moderna's Covid-19 vaccine, Spikevax, which will now be supplied for this year's NHS vaccination campaign directly from UK soil.
A New Era for UK Vaccine Production
The groundbreaking vaccine will be produced at the state-of-the-art Moderna Innovation and Technology Centre located in Harwell, Oxfordshire. This cutting-edge facility is specifically designed to manufacture millions of advanced mRNA vaccines annually, representing a significant leap forward in the UK's pharmaceutical capabilities.
Strategic Partnership and Investment
This development stems from a comprehensive 10-year partnership between Moderna and the UK government, which includes a commitment of over £1 billion in research and development investment within the country. The collaboration aims to strengthen national resilience against Covid-19 and future pandemics by establishing sustainable, domestic vaccine production capabilities.
Darius Hughes, UK General Manager of Moderna, expressed immense pride in this achievement, stating: "With this approval from the MHRA, we are incredibly proud that our LP.8.1 vaccine will be the first commercially available mRNA vaccine manufactured within the UK. By building a sustainable UK-based supply, we are strengthening resilience to Covid-19, future-proofing the UK, and showcasing what British science can achieve when government, industry and researchers work together."
Manufacturing Capacity and Economic Impact
The Harwell facility boasts impressive production capabilities, with the ability to manufacture up to 100 million vaccine doses per year under normal circumstances. During pandemic conditions, this capacity can be scaled up to an impressive 250 million doses annually. Beyond its pharmaceutical output, the centre is expected to create approximately 150 highly skilled jobs, contributing to both the local economy and the UK's scientific workforce.
Broader Implications and Global Context
The approval comes at a significant moment in global health politics. When announcing the facility in September 2025, Moderna's Chief Executive Stephane Bancel specifically noted that the company chose to establish this manufacturing base in a country that "still believes in vaccination." This comment was made against the backdrop of rising anti-vaccination sentiment and science-skeptic attitudes, particularly within certain political administrations including the Trump administration in the United States.
Bancel further elaborated on the strategic thinking behind this UK investment, telling Sky News that if anti-vaccine rhetoric diminishes demand in markets like the United States, the UK operation "may pay dividends." He explained Moderna's business rationale clearly: "If there is less appetite by governments around the world, including in the US, to use vaccines, we might invest less in vaccines. We have to invest where there's a demand for our products."
Future-Proofing UK Health Security
This approval represents more than just another vaccine authorization—it signifies a fundamental shift in how the UK approaches pandemic preparedness. By establishing domestic mRNA vaccine manufacturing capabilities, the country reduces its dependence on international supply chains during health emergencies. The Moderna facility in Oxfordshire stands as a testament to what can be achieved through strategic government-industry collaboration and substantial investment in scientific infrastructure.
The successful approval and upcoming production of mRNA vaccines within the UK marks a pivotal moment for British science, healthcare security, and economic development in the pharmaceutical sector. As the NHS prepares to distribute these domestically manufactured vaccines, the UK positions itself at the forefront of vaccine innovation and production for years to come.
